|Bid||12.00 x 800|
|Ask||12.06 x 1800|
|Day's Range||12.26 - 12.98|
|52 Week Range||11.65 - 27.45|
|Beta (3Y Monthly)||0.48|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jun 6, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||30.40|
-Announced positive Phase 3 results from LIBERTY 1 study evaluating relugolix combination therapy in women with uterine fibroids- -Data from four additional Phase 3 clinical.
Bay Area companies are gearing up for ASCO, HCP's Brisbane biotech building is on the rise and more in our Health Care Digest.
Myovant released topline data from one of the Phase 3 studies, dubbed LIBERTY 1, which evaluated the drug relugolix. The data showed that the study met its primary efficacy endpoint, with 73.4 percent of women receiving the combo therapy achieving a menstrual blood loss volume of less than 80 ml compared to 18.9 percent for placebo. Relugolix, an oral once-daily small molecule acting as a gonadotropin-releasing hormone, is being tested in a 40mg dose in combination with 1mg estradiol and 0.5mg norethindrone acetate.
Shares of Myovant Sciences rose 1.6% in premarket trade Tuesday after the company announced a late-stage study of a uterine fibroid treatment met its primary endpoint and several secondary endpoints. The Phase 3 trial showed that a greater proportion (73.4%) of women on a once-daily combination therapy of the drug showed significant improvement in blood loss than those on placebo (18.9%). Bone density levels in women on the therapy were also comparable to that of those on placebo, and those on the drug experienced on average an 84.3% reduction in menstrual blood loss from baseline, the company said. Relugolix is a once-daily oral drug that blocks receptors for a hormone called gonadotropin-releasing hormone. That reduces the ovaries' production of estradiol, a hormone that stimulates uterine fibroid growth. Myovant shares have gained 5% in the year to date, while the S&P 500 has gained 12%.
Myovant Sciences Ltd said on Tuesday its combination therapy met the main goal of a late-stage study testing the treatment in women with uterine fibroids. The company said 73.4% of women receiving the once-daily treatment showed a greater reduction in menstrual blood loss compared with 18.9% of women receiving placebo. Uterine fibroids are non-cancerous tumors that develop in or on the muscular walls of the uterus and are among the most common reproductive tract tumors, affecting about 5 million women in the United States.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
Myovant Sciences (MYOV), a clinical-stage healthcare company focused on developing and commercializing innovative therapies for women’s health and prostate cancer, today announced that LIBERTY 1, the first of two Phase 3 studies of once daily relugolix combination therapy met its primary efficacy endpoint and six key secondary endpoints in women with uterine fibroids. Relugolix combination therapy maintained bone mineral density at levels comparable to placebo over 24 weeks and was generally well tolerated.
BASEL, Switzerland, May 13, 2019 -- Myovant Sciences (NYSE:MYOV), a clinical-stage healthcare company focused on developing and commercializing innovative therapies for women’s.
Hedge funds are not perfect. They have their bad picks just like everyone else. Facebook, a stock hedge funds have loved, lost nearly 40% of its value at one point in 2018. Although hedge funds are not perfect, their consensus picks do deliver solid returns, however. Our data show the top 15 S&P 500 stocks […]
BASEL, Switzerland , March 5, 2019 /PRNewswire/ -- Myovant Sciences (NYSE: MYOV ), a leading clinical-stage biopharmaceutical company focused on women's health and endocrine diseases, today announced ...
In our view, Myovant (MYOV) is poised for significant value creation in the next 6-12 months, explains John McCamant, biotechnology specialist and editor of The Medical Technology Stock Letter.
The Hamilton, Bermuda-based company said it had a loss of $1.04 per share. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was ...
- Top-line results for LIBERTY 1 and LIBERTY 2 Phase 3 trials in uterine fibroids as well as HERO Phase 3 trial in prostate cancer expected in Q2, Q3 and Q4 2019, respectively - BASEL, Switzerland , Feb. ...
- In addition to Roivant, four Vants will be presenting at JPM this year NEW YORK and BASEL, Switzerland , Jan. 2, 2019 /PRNewswire/ -- Roivant Sciences today announced that Vivek Ramaswamy , Founder and ...
BASEL, Switzerland, Dec. 20, 2018 /PRNewswire/ -- Myovant Sciences (NYSE: MYOV), a leading clinical-stage biopharmaceutical company focused on women's health and endocrine diseases, today announced that Lynn Seely, M.D., President and Chief Executive Officer of Myovant Sciences, will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Myovant's lead product candidate is relugolix, an oral, once-daily small molecule that acts as a GnRH receptor antagonist.
Myovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of women's health and endocrine diseases. Myovant's lead product candidate is relugolix, an oral, once-daily small molecule that acts as a GnRH receptor antagonist.
NEW YORK, Nov. 14, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Completed Patient Enrollment in Phase 3 LIBERTY 1 and HERO Trials - - Completed Screening in Phase 3 LIBERTY 2 Trial - - On Track to Announce Top-line Results from All Five Relugolix Phase 3 Clinical ...
- Kim Sablich, Chief Commercial Officer, and Jeff Nornhold, Senior Vice President, Pharmaceutical Operations & Development, join Myovant's Executive Committee - Myrtle Potter, Mark Guinan and Frank Torti, ...
- Top-line data expected in fourth quarter of 2019 BASEL, Switzerland , Oct. 24, 2018 /PRNewswire/ -- Myovant Sciences (NYSE: MYOV) today announced it has completed patient enrollment in its pivotal Phase ...
BASEL, Switzerland, Oct. 10, 2018 /PRNewswire/ -- Myovant Sciences (NYSE: MYOV) today announced the presentation of data from a Phase 1 trial of MVT-602, a novel kisspeptin-1 receptor agonist in development as a potential treatment for female infertility in women as part of assisted reproduction, such as in vitro fertilization (IVF). Results of the study showed that administration of MVT-602 in healthy premenopausal women in the follicular phase produced a dose-related increase in luteinizing hormone concentrations and expected effects on follicle-stimulating hormone and estradiol.
BASEL, Switzerland and REDWOOD CITY, Calif., Oct. 8, 2018 /PRNewswire/ -- Myovant Sciences (MYOV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women's health and endocrine diseases, and Flo Health, a company developing the world's fastest growing artificial intelligence (AI)-driven platform for women's health with 22 million active users, announced today a partnership to create a digital tool to screen for heavy menstrual bleeding. Affecting more than 25 percent of women, heavy menstrual bleeding is associated with diseases such as uterine fibroids and can negatively impact a woman's quality of life.